Sort by :
Customer Spotlight: Omega Healthcare Celebrates Successful Collaboration with NYU Langone Health
NYU Langone Health team was recently hosted by Anurag Mehta, Co-Founder & CEO of Omega Healthcare, at our India operations. Hear directly from the team.
Omega Healthcare Achieves HITRUST Implemented, 1-year Certification to Manage Cybersecurity Risk and Improve Information Security Posture
HITRUST Implemented, 1-year (i1) Certification validates Omega Healthcare is operating leading security practices to support the protection of sensitive information BOCA RATON, FL, May 16,
CMS RADV Final Rule is Here: How to be Proactive
The Increased Scrutiny Presented by the RADV Final Rule Requires Providers to Remain More Proactive with their Health Plans and Collaborate Better Providers and payers
Omega Healthcare Named “Star Performer” in RCM Operations PEAK Matrix® Assessment 2022
Omega Healthcare Named “Star Performer” in Revenue Cycle Management (RCM) Operations PEAK Matrix® Assessment 2022 Marks the fifth year that Omega has been ranked as
Omega Healthcare Completes Acquisition of ApexonHealth and Vasta Global
Omega Healthcare Completes Acquisition of ApexonHealth and Vasta Global Boca Raton, FL, April 13, 2022: Omega Healthcare, a leading technology-enabled healthcare management solutions provider, today
Tumor Tip of the Week-07-19-2024 Pulse Check 2024 Abstracting
07-19-2024 Pulse Check 2024 Abstracting Most have started abstracting 2024 cases by now, just wanted to do a little check to make sure everyone has
Tumor Tip of the Week 07-12-2024 Clear Cell Papillary Renal Cell Ca-do not use your drop-down menu
Scenario: 2024 RIGHT KIDNEY NEPHRECTOMY: -CLEAR-CELL PAPILLARY RENAL CELL CARCINOMA Question: How would you code histology? 8260 Papillary renal cell carcinoma (C64.9) 8312 Renal cell
Tumor Tip of the Week-06-28-2024 No DRE-No Clinical T, a cT BLANK is better than an assumption
06-28-2024 No DRE-No Clinical T, a cT BLANK is better than an assumption We have seen a trend where Urologists are not performing or not
Tumor Tip of the Week- 06-21-2024 Make sure you are recording all treatment -includes treatment done-recommended-refused-contraindicated
Just as important as it is to code the treatment a patient received, you also need to code when a treatment is not given due
Tumor Tip of the Week 06-07-2024 Radiation Treatment Volume GYN Brachytherapy after TAHBSO
Scenario: • Endometrioid Adenocarcinoma pT3b pN0 treated with TAH/BSO + XRT • Phase 1 XRT: 2/10/2024 to 3/13/2024, Whole pelvis XRT IMRT/6x, 180 cGy x
Tumor Tip of the Week 05-31-2024 Most Specific vs Distinctly Different
Scenario: 2024 Endometrium, curettage: Endometrioid adenocarcinoma, FIGO GR 1 w/ squamous differentiation. TAH/BSO SLN Dissection: Endometrium – Endometrioid adenocarcinoma (FIGO GR 1), confined to the